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Abstract
We examined the capacity of murlne recomblnant tumor necrosis factor (rmTNF) to induce an
inhibitory effect at the hepatic stage on malaria induced by Plasmodium yoelii sporozoltes. When
injected three times, 1.0 /ig of rmTNF was found to protect 78% of mice against a sporozolte
challenge. In contrast, whatever the dose and the schedule of administration, no inhibition was
observed when purified hepatocyte cultures were infected with P. yoelii. The addition of non-
parenchymal hepatic cells to hepatocyte cultures restored the capacity of TNF to modulate
hepatic stage development, leading to up to 44% Inhibition. Antibodies to Interleukin 6 reversed
the anti-parasite activity in the co-culture system.
Introduction
Tumor necrosis factor alpha/cachectin (TNF), initially described
for its ability to induce hemorrhagic necrosis in vivo (1,2), is a
cytokine with various activities, including striking anti-viral (3), anti-
bacterial (4) and anti-parasitic effects (5). In malaria, it has been
shown that TNF administration in vivo protects mice challenged
with parasitized erythrccytes of P. chabaudi (6) and reduces the
development of hepatic forms of P. berghei (7). Although a
previous report indicates that TNF reduced development of
P. berghei in a Hep. G2 hepatoma cell line (7), preliminary data
obtained in our laboratory using fresh hepatocytes did not confirm
this effect. The aim of the present study was to understand the
reasons for such discrepancies and to clarify the role of TNF,
at the hepatic level, in sporozoite induced malaria.
Methods
Animals
Three-month-old BALB/c, C3H/HeJ, and C57B1/6 mice were
purchased from Charles River Breeding Laboratories, Saint-Aubin
les Elbeuf, France.
Cytokines and anti-cytokine antibodies
Murine recombinant TNF alpha (rmTNF) was a kind gift from Dr
B. Allet, Glaxo 1MB, Garouge, Switzerland. Rabbit anti-mouse
TNF IgG was prepared as previously described (8). 6B4, a rat
lgG1 anti-mouse interleukin 6 (IL-6) (9) and murine recombinant
IL-6 (rmlL-6) were a gift from Dr J. Van Snick, Ludwig Institute,
Brussels, Belgium.
Cytokine assays
Supernatants from hepatocyte cultures were assayed for IL-6 in
a bioassay using the 7TD1 cell line as described (10). Secretion
of IFN-gamma in supernatants after stimulation with rmTNF was
measured with an enzyme-linked immunoassay (ELISA) using
a murine monoclonal antibody to IFN-gamma (11). Interleukin
1 (IL-1) was assayed by the standard thymocyte co-mitogen
assay as previously described (12,13).
Parasites
Sporozoites of the 17X strain of Plasmodium yoelii yoelii were
obtained from infected salivary glands of Anopheles stephensi
mosquitoes, 16 to 21 days after an infective mouse blood meal.
After aseptic dissection, salivary glands were homogenized in
a glass grinder and diluted in culture medium or sterile
phosphate-buffered saline (PBS) (14).
In vivo experiments
Balb/c mice were divided into four groups. In the first group, each
mouse received 1.0 /tg of rmTNF intravenously (i-v)- After 24 h,
each animal was injected with 3500 P. yoelii sporozoites i.v. Each
mouse in group 2 received 0.5 /ig rmTNF i.v. 24 h before, during,
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and 24 h after sporozoite inoculation. The third group was treated
as the second group but the rmTNF dose was 1.0 /xg. In the
control group rmTNF was replaced by 0.2 ml of PBS and the
regimen was as for group 2. Blood smears, taken daily from the
third to the seventeenth day after sporozoite inoculation, were
stained with Giemsa and examined for erythrocytic stages of
P. yoeiii.
Culture of hepatic stages of malaria parasites
Monoculture of hepatocytes. Rodent hepatocyte monolayers
(BALB/c, C3H/HeJ, C57BL/6) were isolated by collagenase
perfusion of liver fragments as previously described (15). Briefly,
60 000 cells were cultured in eight-chamber plastic Lab-Teck
slides (Miles Lab. Inc., USA) in minimal essential medium
supplemented with 10% fetal bovine serum and incubated with
5% CO2 at 37°C for 24 h before use in experiments.
Co-culture of hepatocytes and non-parenchymal cells (NPC).
NPC were obtained as already described (16). Briefly, livers from
mice (BALB/c, C57BL/6) were perfused with HEPES buffer
followed by perfusion with 0.05% collagenase (Collagenase H,
Boehringer Mannheim, Germany). Then the distended and
blanched liver was teased and suspended in 30 ml collagenase
solution and maintained for 45 min at 37°C under magnetic
agitation. The suspension was then centrifuged at 300 g for 10
min, the supernatant discarded, and the pellet resuspended in
5 ml HEPES. The liver cell suspension was overlaid with 7 ml
30% w/v metrizamide (Nicomed, Oslo, Norway), dissolved in
HEPES without NaCI. The liver cell metrizamide gradient was
centrifuged at 1400 g for 20 min. NPC were collected from the
top layer, washed twice in HEPES and resuspended in tissue-
culture medium. Sixty thousand viable NPC were added to
primary hepatocyte cultures 3 h after the culture was set up (ratio
1:1).
Treatment of monocultures and co-cultures. Both culture types
were incubated with 0.5,1.0 or 2.5 ^g/ml rmTNF. Control cultures
were maintained without rmTNF. Forty thousand P. yoeiii
sporozoites were added 24 h after rmTNF addition. Three and
24 h after sporozoite inoculation culture supernatants were taken
for cytokine assays and replaced either with fresh medium or
with medium containing rmTNF. Forty-eight hours after sporozoite
inoculation, supernatants were taken again for cytokine assays
and cultures were stopped and stained with Giemsa to find
schizonts. In addition, other cultures of both types were incubated
with 10 ILJ/ml rmlL-6 for 24 h before sporozoites were inoculated;
these cultures were stopped 48 h later.
Neutralization of IL-6 by an anti-IL-6 mAb. Using the same
protocol as described in the previous paragraph, anti-murine IL-6
mAB (1 /100) was added to cultures either at the time of cytokine
incubation or 30 minutes before sporozoite inoculation. The
cultures were then maintained as described above.
Results
In vivo experiments
Injection of 1.0 ng rmTNF the day before, at the time of, and the
day after inoculation of 3500 sporozoites prevented occurrence
of parasitemia in 78% of the mice. This was a consistent finding,
Table 1. Effect of in vivo TNF administration on P. yoeiii
sporozoite infection in BALB/c mice
Treatment
rmTNF (/jg/mouse)























aDe)ay represents the specific mean±SE in the appearance of
parasitemia in non-protected mice, compared to controls injected with
PBS.
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Fig. 1. Effect of TNF in the presence of NPC. 'rmTNF was added at
different times (indicated in hours) after sporozoite inoculation.
Percentage inhibition was estimated by counting numbers of 48-h
schizonts in cultures with or without rmTNF. Results are expressed as
means±SEM of six individual cultures. The controls were either
hepatocytes without NPC (Schizont number: 65 ±3) or hepatocyte with
NPC (Schizont number: 70 ±6).
mice being aparasitaemic 17 days after infection. In the remaining
20% of treated but non-protected mice, the rise in parasitemia
was delayed by a mean of 5 days compared to PBS treated mice.
A single injection of rmTNF (1.0 ^ g/mouse) 24 h before sporozoite
inoculation was much less protective (Table 1). A lower dose of
rmTNF (0.5 ^ g/mouse), even when administered three times (the
day before, on the day of, and 24 h after sporozoite inoculation)
had no protective effect.
In vitro experiments
Effects of TNF on parasite development in vitro. Using BALB/c
hepatocyte monocultures (Fig. 1), no significant parasite inhibi-
tion could be observed when cultures were incubated with 0.5
/ig/ml rmTNF 24 h before sporozoite inoculation. This effect was
not improved by repeating the TNF administration (24 h before,
during, and 24 h after infection), nor by increasing the dose to
2.5 /tg/ml. Similar results were obtained with primary cultures from
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effects (36±5.6% inhibition; Fig. 2), despite the fact that IL-6
remained undetectafcde after 3 h. Neither IFN-7 nor IL-1 could
be detected in primary or in co-culture supernatants at 3,24 and
48 h after sporozoite inoculation, incubated or not with rmTNF.
Effects of murine recombinant IL-6 and its neutralization by an
anti-IL-6 mAb. Incubation of rmlL-6 inhibited parasite develop-
ment up to 42 ±3.3% in primary cultures, while 86 ± 7.0% inhibi-
tion was reached in co-cultures. With an anti-murine IL-6 mAb
(1/100) nearly 90% of the rmlL-6 (10 Ill/ml) induced inhibition
could be neutralized in both primary and co-cultures (Table 2).
Fig. 2. IL-6 levels in culture supernalants. 11.0 /ig/ml, final concentra-
tion 21:100, final dilution. 3Results of six individual cultures, expressed
as means ±SEM, compared to infected hepatocyte cultures without TNF.
The schizont number in untreated control cultures was 86 ± 7. 4 Assayed
3 h after sporozoite inoculation.
Table 2. Effects of in vitro IL-6 incubation on the pre-erythrocytic
parasite development of P. yodii in Balb/c hepatocyte cultures,


























a10 Ill/ml, final concentration.
b1/100, final dilution
cPercentage inhibition of schizont development of six individual
cultures; expressed as means±SEM, compared to infected non-treated
hepatocyte cultures. The schizont number in control cultures was without
NPC 75±4, and with NPC 69 ±5.
C3H/HeJ and C57/BL6 mice (data not shown). The addition of
NPC to hepatocyte cultures (ratio 1:1), in the presence of 0.5
fig TNF resulted in 3 1 % schizont inhibition (Fig. 1). The degree
of inhibition was not improved by repeating the addition of TNF
(24 h before, during, and 24 h after inoculation) nor by increasing
the dose to 2.5 /xg/ml. Identical results were obtained using co-
cultures from C57/BL6 and C3H/HeJ mice (data not shown).
However, incubation of lower doses of rmTNF were less effec-
tive than those shown in Fig. 1 (data not shown).
Effects of TNF-induced IL-6 secretion and its neutralization in
culture supernatants. Purified munne hepatocytes were cultured
alone or in the presence of NPC (co-culture). Both culture types
were incubated with 1.0 nglm\ rmTNF 24 h before sporozoite
inoculation and IL-6 levels were measured in supernatants (Fig.
2). It was found that IL-6 levels were high in co-cultures 3 h after
sporozoite inoculation (mean: 123 U/ml, Fig. 2) and rose to a
mean of 490 U/ml after 48 h, whereas IL-6 was not detectable
in monocultures. Addition of anti-IL-6 mAb to co-cultures at the
time of rmTNF incubation virtually abolished the inhibitory effect
induced by TNF. In contrast, the addition of anti-IL-6 mAb 30
min before sporozoite inoculation did not modify the rmTNF
Discussion
The in vitro studies presented here were performed in order to
define the site and mode of action of TNF. It is shown that when
primary hepatocyte cultures are used instead of tumor cell lines,
TNF fails to induce a protective effect, whatever the dose and
the schedule of administration and whatever the strain of mice.
These results are in contrast to a recent study, where TNF was
found to inhibit development of P. berghei in a Hep. G2 cell line
(7). We have shown that acute-phase proteins (APPs) secreted
after cytokine stimulation (17 -19) inhibit parasite development
in vitro and in vivo (20 - 22). Therefore, the fact that TNF induces
different APPs in tumor cell lines and in normal rat hepatocytes
(23,24) might explain the differences observed in these two
experimental models. Since a TNF dose of 1 ^ g/mouse clearly
protects in vivo without inducing necrosis (25) but has no effect
on hepatocytes in vitro, we questioned whether an in vitro model
containing only hepatocytes was valid. We found in these
experiments that the addition of NPC to hepatocytes restored
the capacity of TNF to modulate parasite hepatic stage develop-
ment (Fig. 1). In our co-culture assay, NPC essentially consist
of pit cells (large granular lymphocytes), Kupffer cells, T-cells,
natural killer cells, endothelial cells from sinusoids, epithelial cells,
fibroblasts and Ito cells. Some of these cells are known to produce
one or several of the following cytokines: IFN-7, IL-1, and IL-6
(26-28), all of which are known to interfere with the hepatic
stages (29-32). We recently demonstrated that IL-6 induces
various effector mechanisms including oxygen radicals (31) and
nitrites (32).
In these co-cultures, markedly elevated IL-6 concentrations
were found upon addition of TNF, whereas IL-1 and IFN-7
remained undetectable. To confirm that IL-6 was directly involved
in the TNF-induced parasite inhibition, anti-IL-6 mAb was added
to mono- and co-cultures of hepatocytes. Anti-IL-6 mAb
dramatically decreased the TNF-induced inhibition when added
24 h before sporozoite inoculation. The preservation of TNF
effects when addition of anti-IL-6 mAb was delayed until 30 min
before sporozoite inoculation showed that the release of IL-6 and
the subsequent modification inside the hepatocytes takes place
in the very early phase of culture after TNF introduction. This is
consistent with the observation of high IL-6 concentrations in 24
and 48 h culture supernatants (data not shown), even when initial
IL-6 production had been neutralized by the addition of anti-IL-6
mAb. The specific inhibitory effect of IL-6 on pre-erythrocytic
stages of parasite development was furthermore demonstrated
by incubating hepatocyte cultures directly with rmlL-6 (Table 2).
These results strongly suggest that IL-6 is a crucial mediator of
the observed TNF effect. The higher inhibitory effect of IL-6 on
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the parasite development observed in the presence of NPC
suggests a stimulation in NPC of additional factors such as yet
to be identified cytokines or substances that act synergistically
with IL-6 (33).
TNF has also been demonstrated to be involved in L-arginine-
dependent cytotoxic effector mechanisms in macrophages (34)
which can have parasiticidal effects (32,35,36).
In malaria the production of various cytokines, and particularly
of TNF, is increased during the blood stage (37,38), and these
cytokines might modulate infection by liver stages. Furthermore,
it has been shown that cytotoxic T cells are involved in the protec-
tion induced by immunization with irradiated sporozoites (39,40).
We recently demonstrated that immunization with peptide
corresponding to the non-repetitive part of the circumsporozoite
of P. yodii, induced CD4+ and CD8+ T cells effective in the
destruction of cultured hepatic schizonts (41; Renia et al., in
preparation). Moreover, these T cells are known to produce
cytokines which include TNF and IL-6 (42). Taken together, these
data further illustrate the interdependence of different stages of
development in malaria parasites.
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